These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 8548057

  • 1. No changes of peripheral insulin resistance in polycystic ovary syndrome after long-term reduction of endogenous androgens with leuprolide.
    Lasco A, Cucinotta D, Gigante A, Denuzzo G, Pedulla M, Trifiletti A, Frisina N.
    Eur J Endocrinol; 1995 Dec; 133(6):718-22. PubMed ID: 8548057
    [Abstract] [Full Text] [Related]

  • 2. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
    Gonzalez F, Hatala DA, Speroff L.
    Am J Obstet Gynecol; 1991 Sep; 165(3):535-45. PubMed ID: 1832519
    [Abstract] [Full Text] [Related]

  • 3. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.
    Rittmaster RS, Thompson DL.
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1096-102. PubMed ID: 2156885
    [Abstract] [Full Text] [Related]

  • 4. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
    Dunaif A, Mandeli J, Fluhr H, Dobrjansky A.
    J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
    [Abstract] [Full Text] [Related]

  • 5. Insulin, C-peptide, androgens, and beta-endorphin response to oral glucose in patients with polycystic ovary syndrome.
    Tropeano G, Lucisano A, Liberale I, Barini A, Vuolo IP, Martino G, Menini E, Dell'Acqua S.
    J Clin Endocrinol Metab; 1994 Feb; 78(2):305-9. PubMed ID: 8106616
    [Abstract] [Full Text] [Related]

  • 6. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G.
    Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
    [Abstract] [Full Text] [Related]

  • 7. Changes in luteinizing hormone and insulin secretion in polycystic ovarian syndrome.
    Fulghesu AM, Cucinelli F, Pavone V, Murgia F, Guido M, Caruso A, Mancuso S, Lanzone A.
    Hum Reprod; 1999 Mar; 14(3):611-7. PubMed ID: 10221684
    [Abstract] [Full Text] [Related]

  • 8. Persistence of hyperinsulinemia in polycystic ovary syndrome after ovarian suppression by gonadotropin-releasing hormone agonist.
    Dale PO, Tanbo T, Djøseland O, Jervell J, Abyholm T.
    Acta Endocrinol (Copenh); 1992 Feb; 126(2):132-6. PubMed ID: 1543018
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Lack of linear relationship between hyperinsulinaemia and hyperandrogenism.
    Toscano V, Bianchi P, Balducci R, Guglielmi R, Mangiantini A, Lubrano C, Sciarra F.
    Clin Endocrinol (Oxf); 1992 Feb; 36(2):197-202. PubMed ID: 1533185
    [Abstract] [Full Text] [Related]

  • 12. Androgen responses to acutely increased endogenous insulin levels in hyperandrogenic and normal cycling women.
    Elkind-Hirsch KE, Valdes CT, McConnell TG, Malinak LR.
    Fertil Steril; 1991 Mar; 55(3):486-91. PubMed ID: 1825813
    [Abstract] [Full Text] [Related]

  • 13. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome.
    Nestler JE, Barlascini CO, Matt DW, Steingold KA, Plymate SR, Clore JN, Blackard WG.
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1027-32. PubMed ID: 2498378
    [Abstract] [Full Text] [Related]

  • 14. Impact of glycemic variations on the regulation of androgen metabolism in obese women with polycystic ovary syndrome.
    Ludwig AK, Goharian LG, Dietze T, Tauchert S, Rudolf S, Diedrich K, Schweiger U, Oltmanns KM.
    Fertil Steril; 2009 Jul; 92(1):271-6. PubMed ID: 18692843
    [Abstract] [Full Text] [Related]

  • 15. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome.
    Romualdi D, De Cicco S, Tagliaferri V, Proto C, Lanzone A, Guido M.
    J Clin Endocrinol Metab; 2011 May; 96(5):E821-4. PubMed ID: 21307134
    [Abstract] [Full Text] [Related]

  • 16. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.
    Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C, Lanzone A.
    Hum Reprod; 2003 Jun; 18(6):1210-8. PubMed ID: 12773448
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations.
    Dale PO, Tanbo T, Vaaler S, Abyholm T.
    Fertil Steril; 1992 Sep; 58(3):487-91. PubMed ID: 1521640
    [Abstract] [Full Text] [Related]

  • 20. Insulin resistance and secretion in polycystic ovarian disease.
    Bruno B, Poccia G, Fabbrini A.
    J Endocrinol Invest; 1985 Oct; 8(5):443-8. PubMed ID: 2934464
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.